Business
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that abstracts discussing the unmet medical needs and the potential benefits of GTx-104 have been accep
About this update from Grace Therapeutics, Inc.
[{"type":"image","alt":"Grace Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Grace Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":238,"height":52,"url":"https://media.zenfs.com/en/globenewswire.com/d9c2bb0e1d56296ef30bd84c47a14138"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LdliIJ9szS3SzFAocDThaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTky/https://media.zenfs.com/en/globenewswire.com/d9c2bb0e1d56296ef30bd84c47a14138","width":238,"height":52}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that abstracts discussing the unmet medical needs and the potential benefits of GTx-104 have been accepted for presentation at two major medical conferences taking place in March 2026.","length":581,"tagName":"p"},{"type":"text","content":"The Company is participating in an industry education workshop during the Society of Critical Care Medicine’s Critical Care Congress, to be held March 22-24, 2026 in Chicago, IL. In a session titled Unmet Needs in aSAH: Limitations of Current Treatments, speakers will discuss the role of orally administered nimodipine as the standard of care for patients with aSAH, including factors that can limit full dosing, such as hypotension and gastrointestinal intolerance. The session will also introduce data from the Company’s Phase 3 STRIVE-ON Trial evaluating GTx-104’s potential to address the shortcomings of oral nimodipine.","length":626,"tagName":"p"},{"type":"text","content":"At the American Association of Neuroscience Nurses annual meeting, to be held March 21-24, in Dallas, TX, the Company will present a poster titled Safety and Tolerability of GTx-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage: a Prospective, Randomized Trial. The poster will highlight data from the STRIVE-ON Trial and the potential of GTx-104 to improve upon the tolerability and dosing consistency of nimodipine therapy compared with oral admini...